Blueprint today announced the latest release of its industry-leading flagship product. The innovative changes announced today will allow Blueprint users to accelerate their IT projects by reviewing artifacts easier and leveraging stronger data protection features.
“As teams tackle the growing demands of complex projects and rising regulation, they can turn to Blueprint to move their projects forward with greater speed, collaboration and security,” said Michael Aronzon, CTO at Blueprint.
Highlights include:
Streamlined Stakeholder Collaboration using Rapid Review
Blueprint’s Rapid Review provides a quick and easy way to share artifacts with team members and gather their feedback. Rapid Review offers the look and feel of reading a traditional document without compromising any Blueprint functionality, and it’s also mobile, accessible on tablets.
Stronger Authentication for improved regulatory compliance
Blueprint has added additional robust data security measures with:
Auto expiration of users’ passwords
- Meaning of Signature (MoS) feature where reviewer’s role and meaning of signature are attached to the e-signature manifestation
- Blueprint users can leverage these features to improve their compliance efforts, particularly with Food and Drug Administration’s (FDA) CFR 21 Part 11 regulation that deals with electronic signature and storage.
“Blueprint knows the value of de-risking your IT project space while meeting compliance requirements,” explained Michael Aronzon, CTO at Blueprint. “For FDA-regulated companies such as drug makers, medical device manufacturers and biotechnology firms, we’ve made it that much easier to meet the regulatory demands.”
More broadly, companies in all regulated industries will benefit directly as these features will also comply with similar data protection requirements.